ALS biomarker research reported an early-warning direction that could improve trial enrollment and patient care planning. A large prospective UK Biobank study identified nine plasma proteins, led by neurofilament light chain, that predicted ALS onset up to a decade before symptoms, including distinct signatures for C9orf72 expansion carriers. This aligns with broader biomarker efforts across neurodegeneration—where measurable changes precede clinical diagnosis. While predictive modeling is not the same as clinical utility, the study design strengthens credibility because of its prospective nature. For the sector, the next step is to test whether biomarker-driven identification improves outcomes: for example, whether earlier interventions can be targeted or whether biomarker strata can enrich clinical trials. Overall, the data support expanding the neurodegeneration pipeline toward earlier detection and precision stratification.